Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014–2018)

Background: A few years after the introduction in Italy of a four-component anti-meningococcal B vaccine (4CMenB), we evaluated the effectiveness and impact of vaccination in two regions using different schedules (2, 4, 6, 12 months in Tuscany vs. 7, 9, 15 months in Veneto) through an observational...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Vaccines (Basel)
Autori principali: Azzari, Chiara, Moriondo, Maria, Nieddu, Francesco, Guarnieri, Valentina, Lodi, Lorenzo, Canessa, Clementina, Indolfi, Giuseppe, Giovannini, Mattia, Napoletano, Giuseppina, Russo, Francesca, Baldovin, Tatjana, Cocchio, Silvia, Ricci, Silvia, Baldo, Vincenzo
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7563708/
https://ncbi.nlm.nih.gov/pubmed/32842669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8030469
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi